Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA3 | P42263 | 1/20 | 0.49 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8107107 | 0.81 | GRIA3 (0.56) | GRIA3GRIA4EPHX2TAS1R3TAS1R1 | |
| SCHEMBL13183222 | 0.79 | GRIA3 (0.47) | GRIA3GRIA4EPHX2TAS1R3TAS1R1 | |
| SCHEMBL13183174 | 0.77 | GRIA3 (0.48) | GRIA3GRIA4EPHX2TAS1R3TAS1R1 | |
| SCHEMBL549310 | 0.72 | GRIA3 (0.51) | GRIA3GRIA4EPHX2TAS1R3TAS1R1 | |
| SCHEMBL8107156 | 0.72 | GRIA3 (0.58) | GRIA3GRIA4TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL548627 | 0.72 | GRIA3 (0.51) | GRIA3GRIA4EPHX2TAS1R3TAS1R1 | |
| SCHEMBL548635 | 0.72 | GRIA3 (0.51) | GRIA3GRIA4EPHX2TAS1R3TAS1R1 | |
| SCHEMBL8114062 | 0.72 | GRIA3 (0.48) | GRIA3GRIA4EPHX2TAS1R3TAS1R1 | |
| SCHEMBL548617 | 0.72 | GRIA3 (0.53) | GRIA3GRIA4EPHX2TAS1R3TAS1R1 | |
| SCHEMBL548613 | 0.72 | GRIA3 (0.50) | GRIA3GRIA4EPHX2TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240300931-A1 | Composition and Methods for Treating Attention Deficit Disorders | LIPPA ARNOLD STAN (US) | 2024-09-12 | — | — | US | claimed |
| US-20240100023-A1 | Compositions and Methods For Treating Spinal Cord Injuries | LIPPA ARNOLD S (US) | 2024-03-28 | — | — | US | claimed |
| US-20230373982-A1 | Compositions And Methods For Treating Attention Deficit Disorders | LIPPA ARNOLD STAN (US) | 2023-11-23 | — | — | US | claimed |
| US-20230129330-A1 | Compositions And Methods For Treating Attention Deficit Disorders | LIPPA ARNOLD STAN (US) | 2023-04-27 | — | — | US | claimed |
| US-20210340130-A1 | Compositions and methods for treating attention deficit disorders | LIPPA ARNOLD STAN (US) | 2021-11-04 | — | — | US | claimed |
| US-20190112300-A1 | Compositions And Methods For Treating Attention Deficit Disorders | LIPPA ARNOLD STAN (US) | 2019-04-18 | — | — | US | claimed |
| US-9492440-B2 | Bicyclic amides for enhancing glutamatergic synaptic responses | RESPIRERX PHARMACEUTICALS INC (US) | 2016-11-15 | — | — | US | claimed |
| EP-2187888-B1 | BICYCLIC AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMA INC (US) | 2015-10-21 | — | — | EP | claimed |
| US-20130190351-A1 | BICYCLIC AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMACEUTICALS, INC. (US) | 2013-07-25 | — | — | US | claimed |
| US-8263591-B2 | Bicyclic amides for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICALS, INC. (US) | 2012-09-11 | — | — | US | claimed |
| US-8110584-B2 | Methods for the treatment of respiratory depression | Cotex Pharmaceuticals, Inc. (US) | 2012-02-07 | — | — | US | claimed |
| US-20110003835-A1 | Methods for the treatment of respiratory depression | CORTEX PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | claimed |
| US-20100286177-A1 | BICYCLIC AMIDES FOR THE TREATMENT OF RESPIRATORY DEPRESSION | CORTEX PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | US | claimed |
| EP-2233140-A1 | Bicyclic amides for enhancing glutamatergic synaptic responses | Biovail Laboratories International SRL (BB) | 2010-09-29 | — | — | EP | claimed |
| EP-2187888-A2 | BICYCLIC AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMACEUTICALS, INC. (US) | 2010-05-26 | — | — | EP | claimed |
| WO-2009023126-A2 | BICYCLIC AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMACEUTICALS, INC. (US) | 2009-02-19 | — | — | WO | claimed |
| US-20240355686-A1 | Clinical Methods and Pharmaceutical Compositions Employing AMPA Receptor Antagonists to Treat Glioblastoma and Other Cancers | RADIN DANIEL PIERCE (US) | 2024-10-24 | — | — | US | disclosed |
| US-20240300931-A1 | Composition and Methods for Treating Attention Deficit Disorders | LIPPA ARNOLD STAN (US) | 2024-09-12 | — | — | US | disclosed |
| US-20100286177-A1 | BICYCLIC AMIDES FOR THE TREATMENT OF RESPIRATORY DEPRESSION | CORTEX PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | US | disclosed |
| EP-2233140-A1 | Bicyclic amides for enhancing glutamatergic synaptic responses | Biovail Laboratories International SRL (BB) | 2010-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210340130-A1 | Compositions and methods for treating attention deficit disorders | GRIN2A, GRIN2C, GRM2 | GRIA3 32/4885GRIA4 38/4885EPHX2 1545/4885 |
| US-20240100023-A1 | Compositions and Methods For Treating Spinal Cord Injuries | CHAT, NTRK2, GMFG | GRIA3 38/4885GRIA4 37/4885EPHX2 1253/4885 |
| US-20130190351-A1 | BICYCLIC AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | BDNF, GRIN2A, SLC18A2 | GRIA3 17/4885GRIA4 23/4885EPHX2 1638/4885 |
| US-20110003835-A1 | Methods for the treatment of respiratory depression | BDNF, CHRNA10, CHRNA3 | GRIA3 93/4885GRIA4 246/4885EPHX2 3066/4885 |
| US-20230129330-A1 | Compositions And Methods For Treating Attention Deficit Disorders | GRIN2A, GRIN2C, GRM2 | GRIA3 32/4885GRIA4 38/4885EPHX2 1545/4885 |
| US-20100286177-A1 | BICYCLIC AMIDES FOR THE TREATMENT OF RESPIRATORY DEPRESSION | BDNF, HCRTR2, CHRNA10 | GRIA3 165/4885GRIA4 436/4885EPHX2 2325/4885 |
| US-20230373982-A1 | Compositions And Methods For Treating Attention Deficit Disorders | GRIN2A, GRIN2C, GRM2 | GRIA3 32/4885GRIA4 38/4885EPHX2 1545/4885 |
| US-20240300931-A1 | Composition and Methods for Treating Attention Deficit Disorders | GRIN2A, GRIN2C, NTRK2 | GRIA3 38/4885GRIA4 40/4885EPHX2 1547/4885 |
| US-20190112300-A1 | Compositions And Methods For Treating Attention Deficit Disorders | GRIN2A, GRIN2C, GRM2 | GRIA3 32/4885GRIA4 38/4885EPHX2 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.